Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On August 17th, Autobio released a semi-annual performance report stating that the operating income was 1.678 billion yuan, an increase of 39.13% year-on-year; the net profit attributable to shareholders of listed companies was 413 million yuan, an increase of 50.63% year-on-year.

A federal jury on Friday ruled that Qiagen willfully infringed two patents owned by ArcherDx (now part of Invitae) and Massachusetts General Hospital and ruled that Qiagen must pay royalties and lost profits totaling about $4.7 million.

The Medical Device Coordination Group (MDCG) has published guidance MDCG 2021-21 “Guidance on performance evaluation of SARS-CoV-2 in vitro diagnostic medical devices” – the document is critical for all manufacturers who manufacture and have CE marked COVID-19 tests under the IVD Directive (IVDD).

LumiraDx reduced the terms of the valuation for its SPAC merger from $5 billion to$3 billion citing a decline in COVID-19 testing

The US Food and Drug Administration this week granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Mount Sinai Hospital and Empire City Laboratories.

Genetron Health collaborates with Yikon Genomics, expanding S5 Platform's reach to reproductive health field; AmoyDx collaborates with Amgen to develop companion diagnostics for Japan market; AcornDx collaborates with BGI to develop accurate diagnosis on urinary system tumors

MDxHealth reported Thursday after the close of the Belgian stock exchange that its revenues for the first half of 2021 increased 9 percent year over year.

Thermo Fisher Scientific said on Wednesday that the US Food and Drug Administration has granted pre-market approval to the company's Oncomine Dx Target Test as a companion diagnostic to identify patients with isocitrate dehydrogenase-1 (IDH1) mutated cholangiocarcinoma (CCA)

August 25, Mindray (300760.SZ) announced financial results for the first half ended June 30, 2021. The first-half sales of CNY 12.778 billion increased 20.96% year-on-year. The net earnings attributable to common stockholders was CNY 4.344 billion, increasing 25.79% than the one in the last year.

AccessDx Holdings said Wednesday that it has acquired 2bPrecise, a service and technology provider that integrates genetic and genomic test results into electronic health records, from EHR giant Allscripts Healthcare Solutions for an undisclosed amount.